Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Surface Oncology, Inc. (SURF) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Surface Oncology, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1718108.
Total stock buying since 2018: $42,496,090.
Total stock sales since 2018: $69,320,764.
Total stock option exercises since 2018: $1,182,385.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 37,090 | $34,862 | 0 | $0 |
| 2022 | 0 | $0 | 31,176 | $53,620 | 0 | $0 |
| 2021 | 0 | $0 | 521,591 | $3,709,269 | 255,000 | $1,046,099 |
| 2020 | 5,000 | $16,150 | 4,159,780 | $65,523,013 | 6,278 | $26,826 |
| 2019 | 0 | $0 | 0 | $0 | 30,001 | $109,460 |
| 2018 | 2,831,996 | $42,479,940 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-08 | 0 | $0 | 37,090 | $34,862 | 0 | $0 |
| 2022-08 | 0 | $0 | 31,176 | $53,620 | 0 | $0 |
| 2021-07 | 0 | $0 | 248,591 | $1,516,402 | 0 | $0 |
| 2021-06 | 0 | $0 | 250,000 | $1,914,940 | 245,000 | $1,014,299 |
| 2021-02 | 0 | $0 | 9,000 | $104,777 | 5,000 | $15,900 |
| 2021-01 | 0 | $0 | 14,000 | $173,150 | 5,000 | $15,900 |
| 2020-12 | 0 | $0 | 3,402,405 | $61,564,600 | 0 | $0 |
| 2020-11 | 0 | $0 | 595 | $5,979 | 1,383 | $6,253 |
| 2020-10 | 0 | $0 | 4,000 | $40,200 | 4,895 | $20,573 |
| 2020-09 | 0 | $0 | 332,780 | $2,376,714 | 0 | $0 |
| 2020-05 | 0 | $0 | 420,000 | $1,535,520 | 0 | $0 |
| 2020-02 | 5,000 | $16,150 | 0 | $0 | 0 | $0 |
| 2019-04 | 0 | $0 | 0 | $0 | 2,728 | $960 |
| 2019-01 | 0 | $0 | 0 | $0 | 27,273 | $108,500 |
| 2018-04 | 2,831,996 | $42,479,940 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-08-01 | Adams Chandra (Deputy GC) | Sale | 3,901 | .94 | 3,666 |
| 2023-08-01 | Fees Jessica (Chief Financial Officer) | Sale | 9,434 | .94 | 8,867 |
| 2023-08-01 | Ross Robert W. (Chief Executive Officer) | Sale | 16,713 | .94 | 15,710 |
| 2023-08-01 | Oneill Alison (Chief Medical Officer) | Sale | 7,042 | .94 | 6,619 |
| 2022-08-03 | Rath Henry C. (Chief Business Officer) | Sale | 5,676 | 1.72 | 9,762 |
| 2022-08-03 | Fees Jessica (Chief Financial Officer) | Sale | 5,980 | 1.72 | 10,285 |
| 2022-08-03 | Ross Robert W. (Chief Executive Officer) | Sale | 10,594 | 1.72 | 18,221 |
| 2022-08-03 | Palombella Vito J. (Chief Scientific Officer) | Sale | 4,463 | 1.72 | 7,676 |
| 2022-08-03 | Oneill Alison (Chief Medical Officer) | Sale | 4,463 | 1.72 | 7,676 |
| 2021-07-21 | Fees Jessica (Chief Financial Officer) | Sale | 19,854 | 6.10 | 121,109 |
| 2021-07-21 | Nogelo Liisa I (Chief Legal Officer) | Sale | 26,325 | 6.10 | 160,582 |
| 2021-07-21 | Ross Robert W. (Chief Executive Officer) | Sale | 33,500 | 6.10 | 204,350 |
| 2021-07-21 | Goater Jeff (Director) | Sale | 127,778 | 6.10 | 779,445 |
| 2021-07-21 | Palombella Vito J. (Chief Scientific Officer) | Sale | 26,325 | 6.10 | 160,582 |
| 2021-07-21 | Oneill Alison (Chief Medical Officer) | Sale | 14,809 | 6.10 | 90,334 |
| 2021-06-11 | Goater Jeff (Director) | Sale | 15,273 | 7.61 | 116,227 |
| 2021-06-11 | Goater Jeff (Director) | Option Ex | 10,273 | 4.14 | 42,530 |
| 2021-06-10 | Goater Jeff (Director) | Sale | 234,727 | 7.66 | 1,798,713 |
| 2021-06-10 | Goater Jeff (Director) | Option Ex | 234,727 | 4.14 | 971,769 |
| 2021-02-16 | Ross Robert W. (Chief Medical Officer) | Sale | 1,000 | 11.35 | 11,350 |
| 2021-02-08 | Fees Jessica (See Remarks) | Sale | 1,500 | 12.45 | 18,675 |
| 2021-02-08 | Goater Jeff (Chief Executive Officer) | Sale | 2,500 | 12.50 | 31,250 |
| 2021-02-08 | Goater Jeff (Chief Executive Officer) | Option Ex | 2,500 | 3.18 | 7,950 |
| 2021-02-01 | Fees Jessica (See Remarks) | Sale | 1,500 | 11.19 | 16,785 |
| 2021-02-01 | Goater Jeff (Chief Executive Officer) | Sale | 2,500 | 10.69 | 26,717 |
| 2021-02-01 | Goater Jeff (Chief Executive Officer) | Option Ex | 2,500 | 3.18 | 7,950 |
| 2021-01-19 | Goater Jeff (Chief Executive Officer) | Sale | 5,000 | 13.00 | 65,000 |
| 2021-01-19 | Goater Jeff (Chief Executive Officer) | Option Ex | 5,000 | 3.18 | 15,900 |
| 2021-01-15 | Ross Robert W. (Chief Medical Officer) | Sale | 2,000 | 12.25 | 24,500 |
| 2021-01-14 | Ross Robert W. (Chief Medical Officer) | Sale | 7,000 | 11.95 | 83,650 |
| 2020-12-17 | Grayzel David S. (Director) | Sale | 1,700,000 | 18.10 | 30,770,000 |
| 2020-12-17 | Atlas Venture Associates Ix, Llc (10% Owner) | Sale | 1,700,000 | 18.10 | 30,770,000 |
| 2020-12-15 | Ross Robert W. (Chief Medical Officer) | Sale | 1,000 | 10.48 | 10,480 |
| 2020-12-11 | Ross Robert W. (Chief Medical Officer) | Sale | 1,405 | 10.05 | 14,120 |
| 2020-11-25 | Fees Jessica (See Remarks) | Option Ex | 1,383 | 4.52 | 6,253 |
| 2020-11-11 | Ross Robert W. (Chief Medical Officer) | Sale | 595 | 10.05 | 5,979 |
| 2020-10-28 | Fees Jessica (See Remarks) | Option Ex | 4,895 | 4.20 | 20,573 |
| 2020-10-14 | Ross Robert W. (Chief Medical Officer) | Sale | 4,000 | 10.05 | 40,200 |
| 2020-09-01 | Ecor1 Capital, Llc | Sale | 332,780 | 7.14 | 2,376,714 |
| 2020-05-20 | Sonsini Peter W. (10% Owner) | Sale | 420,000 | 3.66 | 1,535,520 |
| 2020-02-05 | Goater Jeff (Chief Executive Officer) | Buy | 5,000 | 3.23 | 16,150 |
| 2019-04-01 | Fees Jessica (See Remarks) | Option Ex | 2,728 | .35 | 960 |
| 2019-01-04 | Fees Jessica (See Remarks) | Option Ex | 2,273 | 2.24 | 5,100 |
| 2019-01-04 | Ross Robert W. (Chief Medical Officer) | Option Ex | 25,000 | 4.14 | 103,400 |
| 2018-04-23 | Grayzel David S. (Director) | Buy | 100,000 | 15.00 | 1,500,000 |
| 2018-04-23 | Atlas Venture Associates Ix, Llc (10% Owner) | Buy | 100,000 | 15.00 | 1,500,000 |
| 2018-04-23 | Shanafelt Armen (Director) | Buy | 266,000 | 15.00 | 3,990,000 |
| 2018-04-23 | Hall Steven Edward (10% Owner) | Buy | 266,000 | 15.00 | 3,990,000 |
| 2018-04-23 | Florence Anthony A. Jr. (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Sonsini Peter W. (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | New Enterprise Associates 14, L.p. (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Viswanathan Ravi (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Baskett Forest (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Sandell Scott D (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Kerins Patrick J (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Mott David M (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Barrett M James (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2018-04-23 | Novartis Ag (10% Owner) | Buy | 766,666 | 15.00 | 11,499,990 |
| 2018-04-23 | Barris Peter J (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
Insider trading activities including stock purchases, stock sales, and option exercises of SURF listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Surface Oncology, Inc. (symbol SURF, CIK number 1718108) see the Securities and Exchange Commission (SEC) website.